Vir Biotechnology Announces Pricing of Public Offering of Common Stock

Core Viewpoint - Vir Biotechnology, Inc. has announced the pricing of its public offering of common stock, aiming to raise $150 million through the sale of 17,647,058 shares at $8.50 per share, with a potential additional option for underwriters to purchase up to 2,647,058 shares [1] Group 1: Offering Details - The public offering consists of 17,647,058 shares priced at $8.50 each, expected to generate gross proceeds of $150 million before expenses [1] - Underwriters have a 30-day option to purchase an additional 2,647,058 shares at the public offering price [1] - The offering is set to close on February 27, 2026, pending customary closing conditions [1] Group 2: Underwriters and Registration - Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI, and Barclays are acting as book-running managers for the offering [1] - The shares are being offered under an automatically effective shelf registration statement filed with the SEC on November 3, 2023 [1] Group 3: Company Overview - Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing medicines for serious infectious diseases and cancer [1] - The company's clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers targeting solid tumors [1]